anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide a drink free from the peculiar smell of the raw materials and agreeable to drink, by adding a distilled fraction of a plant belonging to Theaceae family to a drink such as soya milk, vegetable juice, herb extract drink, etc. CONSTITUTION:The distilled fraction of a plant belonging to Theaceae family, e.g. tea, sasanqua camellia, common camellia, HISAKAKI (Eurya japonica) etc. is added to a drink such as soya milk, vegetable juice, ginseng drink, etc. The amount of the fraction is e.g. 1-2 drops as a diluted aqueous solution to 200ml of soya milk.
Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
Potential volunteers will be screened by telephone. Those meeting all inclusion and no exclusion criteria will be invited to a screening study visit. At screening, informed consent will be obtained. The study team will then collect the following to determine study eligibility: basic demographic information (age, ancestry, and education); medical history; medication and supplement use; and blood for screening 25(OH)D and calcium tests. At baseline, participants will be randomly assigned to the control or dosing algorithm group. Both participants and study staff who have contact with the participants will be blinded to group assignment. Follow-up visits will occur at three and six months. At baseline and follow-up visits, height and weight will be measured and blood will be drawn for the vitamin D panel, calcium, and PTH. Blood for DNA and body composition will only be obtained at the baseline visit. Participants will be asked to return all unused study supplements and compliance will be assessed at each follow-up visit by pill count. The control group will receive 2500 IU of vitamin D3 daily while the dosing algorithm group will initially receive 1000, 2500, or 4000 IU daily, with the initial dosing based on the 25(OH)D at baseline, and the dosing may be adjusted at the 3-month visit.
The patients enrolled for the study will be women scheduled for breast MRI due to high risk screening or pretreatment evaluation. The patients will fill in a form regarding: age, hormonal status, risk factors, prior breast surgery or treatment (a form which is routinely filled out in our institution). They will then undergo a breast MRI scan, using the routine protocol in our institution. This will be directly followed by a DTI sequence, which takes about 10 minutes in addition to the regular examination. The DTI sequence is routinely used in other imaging institutions, as part of the breast MRI protocol.
WARNING: SERIOUS SKIN RASHES

SUBVENITE can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 to 17 years) and 0.08% to 0.3% in adults receiving SUBVENITE. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking SUBVENITE as adjunctive therapy. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.

Other than age, there are as yet no factors identified that are known to predict the risk of occurrence or the severity of rash caused by SUBVENITE. There are suggestions, yet to be proven, that the risk of rash may also be increased by (1) coadministration of SUBVENITE with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of SUBVENITE, or (3) exceeding the recommended dose escalation for SUBVENITE. However, cases have occurred in the absence of these factors.

Nearly all cases of life-threatening rashes caused by SUBVENITE have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.

Although benign rashes are also caused by SUBVENITE, it is not possible to predict reliably which rashes will prove to be serious or life threatening. Accordingly,SUBVENITE should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug related. Discontinuation of treatment may not prevent a rash from becoming life threatening or permanently disabling or disfiguring [see Warnings and Precautions ( 5.1)] .
The invention relates to a water lily kneepad thermotherapy bag and a manufacturing method thereof. The thermotherapy bag is made of water lily, rhizoma atractylodis, phellodendron, cyathula root, red sage root, iron powder, active carbon, vermiculite, coarse salt, and non-woven cloth, and is prepared through steps of stitching, grinding, drug filling, and packaging in vacuum. The thermotherapy bag is applied to the affected part externally, can be used to treat joint ache caused by strain or inappropriate gesture and knee ache due to osteoarthritis or rheumatic arthritis, and is a novel healthcare product. The water lily contains alkaloid, tannin, flavonoid, anthocyanidin, multiple amino acids, vitamins, and trace elements such as iron, selenium, and the like. When the bag is used, people should roll and knead the kneepad thermotherapy bag until the bag has a hot feeling, then the bag is tied on the knee to make the pharmaceutical components slowly penetrate into the skin after the pharmaceutical components go through the clothes; and the bag has the functions of tranquilizing, calming the nerve, relieving pains, dissipating cold, and freeing the collaterals and meridians. The water lily kneepad thermotherapy bag has a prominent curative effect on knee osteoarthritis, hyperostosis, rheumatoid arthritis, gouty arthritis, and the like.
Usual Dose for Acute Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder in Adults: 

Monotherapy: The recommended starting dose of SAPHRIS, and the dose maintained by 90% of the patients studied, is 10 mg twice daily. The dose can be decreased to 5 mg twice daily if warranted by adverse effects or based on individual tolerability.

In controlled monotherapy trials, the starting dose for SAPHRIS was 10 mg twice daily. On the second and subsequent days of the trials, the dose could be lowered to 5 mg twice daily, based on tolerability, but less than 10% of patients had their dose reduced. The safety of doses above 10 mg twice daily has not been evaluated in clinical trials.

Adjunctive Therapy: The recommended starting dose of SAPHRIS is 5 mg twice daily when administered as adjunctive therapy with either lithium or valproate. Depending on the clinical response and tolerability in the individual patient, the dose can be increased to 10 mg twice daily. The safety of doses above 10 mg twice daily as adjunctive therapy with lithium or valproate has not been evaluated in clinical trials.

### 

Maintenance Treatment: While there is no body of evidence available to answer the question of how long the bipolar patient should remain on SAPHRIS, whether used as monotherapy or as adjunctive therapy with lithium or valproate, it is generally recommended that responding patients be continued beyond the acute response. If SAPHRIS is used for extended periods in bipolar disorder, the physician should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.
PCT No. PCT/FR94/00409 Sec. 371 Date Jul. 20, 1995 Sec. 102(e) Date Jul. 20, 1995 PCT Filed Apr. 13, 1994 PCT Pub. No. WO94/23832 PCT Pub. Date Oct. 27, 1994Particles, preparation methods therefor, and compositions containing same. The particles include at least one esterified polysaccharide and at least one polyamine, as well as at least one gellable polysaccharide when neither the esterified polysaccharide nor the polyamine can be gelled under the selected operating conditions. Said particle includes, at least on its surface, a membrane consisting of the product of the transacylation reaction between the esterified polysaccharide and said polyamine within an optionally gellable gel, said reaction causing the formation of covalent amide bonds. Such particles may be used to encapsulated various active principles useful in the fields of cosmetics, pharmaceuticals and agri-foodstuffs, enzymes, cells and micro-organisms.
T regulatory cells (T regs) are a recently identified subset of T cells with inhibitory functions on the immune system. In cancer, it has been shown that there is an increased proportion of T regs in several different human malignancy states. T regs are found to be elevated in peripheral blood mononuclear cells, draining lymph nodes and in the primary tumor itself. There has also been correlation between peripheral blood T regs and tumor stage, tumor relapse and survival. It has been proposed that the T regs are activated and expanded by factors produced by the tumor microenvironment. They are thought to play a role in preventing or demising host T-cell responses against cancer, including a suboptimal host responses to vaccine strategies. Strategies to reduce T regs in cancer patients are being explored as a novel immunologic anti-cancer approach.

Renal cell cancer (RCC) is a tumor with well-known immune-mediated phenomena such as spontaneous regression. There is paucity of data on T regs in RCC. We propose to study the frequency of peripheral blood T regs before and after nephrectomy for RCC. We will document the baseline frequency of T regs in RCC and if nephrectomy results in a change in levels. We hypothesize that nephrectomy will lower peripheral T regs to normal levels in early stage RCC, and will reduce peripheral T reg levels in advanced RCC patients. If found to be so, T regs could in future be used as an indicator of disease recurrence in early stage RCC. In advanced RCC, lowering of T reg levels may help explain the previous hypothesis that debulking nephrectomy results in improved anti-tumor immunity, provide rationale for second debulking procedures, and be correlated with subsequent clinical course.

The main laboratory technique is flow cytometry. This will be a pilot study with small patient numbers. Only blood samples are required.
PURPOSE: A method of treating coronavirus infection including SARS by administration of a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist is provided. It is effective in reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in patients suffering from a coronavirus infection. The composition for treating coronavirus infection including SARS contains a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist. CONSTITUTION: The coronavirus infection including SARS is performed by the step of administration of a therapeutically effective amount of IFN-alpha and IFN-gamma to an individual, in which the individual is exposed to coronavirus and the IFN-alpha and IFN-gamma are administered within 24hr, 48hr or 72hr or 35 days. A Type I or III interferon receptor agonist can be administered daily, twice daily, every other day, twice a week, three times a week. Effective dosages of a Type I interferon receptor agonist can range from about 1 to about 180micrograms. The Type I interferon receptor agonist is IFN-alpha. The IFN-alpha and IFN-gamma are administered subcutaneously in multiple doses. The method of treating a coronavirus infection is effective in reducing the risk that an individual will develop a pathological coronavirus infection, which has clinical sequelae.
This invention relates to the therapeutic induction of apoptosis in activated inflammatory cells, or cells at a site of inflammation, by introducing into those cells a chimeric gene containing an apoptosis-inducing gene (AIG) driven by a promoter of an inducible gene activated in inflammation and a promoter enhancer such that the inflammatory cells are targeted. In one embodiment, the chimeric gene comprises at least one TNFα promoter enhancer attached to a functional copy of a minimal TNFα promoter and further attached to at least one copy of an apoptosis-inducing gene, wherein expression of the gene is driven by the TNFα promoter. Attachment can be direct, distal, proximal or combinations thereof. Example apoptosis-inducing genes include caspase 3, caspase 4, caspase 5, Granzyme B. Advantageously, the TNFp-AIG chimeric gene is expressed in only those cells producing the inflammatory cytokine, TNFα. In addition, the TNFp-AIG chimeric gene also sequesters inducible TNFp transcription factors, thereby reducing endogenous production of TNFα. The invention also relates to methods of making and using self-regulated apoptosis chimeric genes and pharmaceutical compositions containing them for treating inflammatory diseases.
Attenuating, while in a given situation, a person's emanated electromagnetic field and the person's scent or odor, by the person wearing article(s) of apparel that include an electromagnetically shielding fabric. The shielding fabric comprises a substantially continuous system of conductive fibers combined with a non-conductive fabric. The conductive fibers attenuate both the emanated electromagnetic field and the emanated scent or odor. The given situation comprises hunting, animal handling, being in or on a body of water, or a human adversarial situation. Attenuating the person's emanated electromagnetic field decreases the likelihood of that emanated field affecting progress or an outcome of the given situation. Attenuating the person's emanated scent or odor decreases the likelihood of that emanated scent or odor affecting progress or the outcome of the given situation.
Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Non-specific treatment.(Chinese herbal medicine and nonspecific immunomodulators as adjuvant anti-cancer treatment for 2 years).
Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Adequate facilities should be available for postoperative monitoring and ventilation of patients administered anesthetic doses of Fentanyl Citrate Injection. It is essential that these facilities be fully equipped to handle all degrees of respiratory depression. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status [see Overdosage (10)]. Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. 

To reduce the risk of respiratory depression, proper dosing and titration of Fentanyl Citrate Injection are essential. As with other potent opioids, the respiratory depressant effect of Fentanyl Citrate Injection may persist longer than the measured analgesic effect. The total dose of all opioid agonists administered should be considered by the practitioner before ordering opioid analgesics during recovery from anesthesia. 

Certain forms of conduction anesthesia, such as spinal anesthesia and some peridural anesthetics, can alter respiration by blocking intercostal nerves through other mechanisms [see Clinical Pharmacology (12.2)]. Fentanyl Citrate Injection can also alter respiration. Therefore, when Fentanyl Citrate Injection is used to supplement these forms of anesthesia, the anesthetist should be familiar with the physiological alterations involved, and be prepared to manage them in the patients selected for these forms of anesthesia. 

Patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of Fentanyl Citrate Injection. Elderly, cachectic, or debilitated patients may have altered pharmacokinetics or altered clearance compared to younger, healthier patients resulting in greater risk for respiratory depression. 

Monitor such patients closely including vital signs, particularly when initiating and titrating Fentanyl Citrate Injection and when Fentanyl Citrate Injection is given concomitantly with other drugs that depress respiration. To reduce the risk of respiratory depression, proper dosing and titration of Fentanyl Citrate Injection are essential [see Dosage and Administration (2.1)].

Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see Dosage and Administration (2.1)].
Infants in this group received the Algidex patch on top of the line insertion sites of any of the following lines: umbilical arterial line, umbilical venous line, peripheral arterial line, peripheral long line, and central venous line. This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2. Every 7 days, each insertion site was cleansed and then a new patch was placed and covered with a fresh occlusive dressing (Tegaderm, Opsite).
Despite its relatively high rate of occurrence, autism spectrum disorder (ASD) is under-diagnosed and under-treated in young children, particularly in minority and disadvantaged populations. Although screening for ASD in the primary care setting is recommended as best practice, inadequate attention has been paid to addressing important obstacles to early recognition of ASD, including barriers to referral after positive screening, completion of diagnostic evaluations, and receipt of treatment. Patient navigation was originally developed to reduce health care disparities. The patient navigator guides patients with suspicious findings (e.g., a positive screening test) through and around barriers to care to ensure timely diagnosis and treatment. Patient navigation has improved receipt of preventive care among low-income, minority children but has not been tested for improving early identification and treatment of autism spectrum disorders. The goal of this study is to test the effectiveness and feasibility of patient navigation to facilitate autism screening follow-up, diagnostic evaluation, and linkage to early intervention in a very young, disadvantaged, minority population. To increase patient navigation's potential for widespread application and public health impact, this study uses the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework, a set of criteria for translating research into action, to guide planning and evaluation. The intervention's Reach, Effectiveness, Adoption, Implementation and Maintenance over time will be examined.
1,214,936. Kava active substances. SPEZIAL -CHEMIE G.m.b.H. & CO. 5 June, 1968 [5 June, 1967], No. 26690/68. Heading A5B. Endoanaesthetic, muscle-relaxing, sleepinducing and psychotroparactic solutions are prepared by dissolving two or more kava active substances selected from yangonin, kawain, dihydrokawain, dehydrokawain, 5,6-dehydro-7,8- dihydrokawain, p- and mnitrokawain, p- and m-aminokawain, kawain hydrochloride and kawain hydrobromide in one or more saturated or unsaturated oily solvents. The oily solvent may be a vegetable oil such as peanut, soya, sunflower, linseed or neatsfoot oil; an adipate, isoadipate, alkyl-branched fatty acid ester, polyglycol or polyglycol adduct, polyethylene oxide derivatives of different chain length, condensation products of fatty acids with polyglycols or other polyethylene oxide adducts or fatty acid glycerine esters. In a modification, the oily solvent may be replaced by dimethyl sulphoxide or 2-dimethyl-4-methoxy-1,3- dioxolane. The powered kava active substances may be thoroughly mixed before dissolution, which is preferably carried out with heating to a temperature corresponding to the melting point of the kava active substances being dissolved. A preferred composition contains yangonin, kawain and dihydrokawain. The solutions may be formulated as gelatin capsules.
Participants will receive 160 locomotor training sessions with epidural stimulation. These sessions may occur once a day (stand and step will alternate days) or twice a day (stand and step on the same day) as recommended by the study physician. Participants will train 5 days per week and each session will last between 1 to 1.5 hours.
The present invention discloses a preparation method and a medicinal purpose of an embryo factor of fowls (all birds and fowls). A fowl embryo is put into a tissue mincer to be homogenized, and the homogenized fowl embryo is centrifugally filtered after being repeatedly melted by ice, and then the effective components are extracted by an ultrafiltration method or a dialysis method. The injection liquid of the fowl embryo factor is colorless and transparent, the pH value is 7(+/-)3, and the molecular weight is less than or equal to 30, 000. The content of polypeptide of the injection liquid of the fowl embryo factor is more than 1000 ug/ml, and the content of ribonucleic acid is more than 100 ug/ml. The embryo factor has the advantages of high safety and no toxic or side effect, can induce LAK cells and can activate NK cells, and thereby, the NK cells generate strong action of killing cancer, and the factor can be used for adoptive immunity therapy of tumor. In addition, the factor preparation can directly kill cancer cells, obviously enhances immunological functions and has certain aging-resistance action.
On Day 1, participants receive a single dose of \[¹⁴C\]opevesostat as an oral solution. Participants then receive single doses of 5.0 mg prednisone and 0.05 mg fludrocortisone tablets 4 hours later as hormone replacement therapy.
To assess the diagnostic performance of three cardiothoracic (CT) ratio techniques, including diameter, circumference, and area, for predicting hemoglobin (Hb) Bart's disease between 17 and 22 weeks' gestation, and to create a multivariable scoring system using multiple ultrasound markers. Before invasive testing, three CT ratio techniques and other ultrasound markers were obtained in 151 singleton pregnancies at risk of Hb Bart's disease. CT diameter ratio demonstrated the highest sensitivity among the other techniques. Significant predictors included CT diameter ratio > 0.5, middle cerebral artery-peak systolic velocity (MCA-PSV) > 1.5 multiples of the median, and placental thickness > 3 cm. MCA-PSV exhibited the highest sensitivity (97.8%) in predicting affected fetuses. A multivariable scoring achieved excellent sensitivity (100%) and specificity (84.9%) for disease prediction. CT diameter ratio exhibited slightly outperforming the other techniques. Increased MCA-PSV was the most valuable ultrasound marker. Multivariable scoring surpassed single-parameter analysis in predictive capabilities.